Innate Pharma
IPHA
About: Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Employees: 181
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.08% less ownership
Funds ownership: 0.19% [Q1] → 0.11% (-0.08%) [Q2]
10% less funds holding
Funds holding: 10 [Q1] → 9 (-1) [Q2]
36% less capital invested
Capital invested by funds: $282K [Q1] → $179K (-$103K) [Q2]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Financial journalist opinion
